Health Care·Biotechnology·$2.7B
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $-0.40 | N/A | -26.18% |
| Revenue | N/A | N/A | N/A |
management commentary, guidance changes, and full analysis available with Pro.
| EPS | $-0.40 | N/A | -26.18% |
| Revenue | N/A | N/A | N/A |
Tone: Defensive
Management expressed concern over the recent performance but remains committed to their strategic goals. They did not provide specific guidance for future quarters.
Management acknowledged the challenges faced during the quarter.
They emphasized a focus on long-term growth despite current setbacks.
Veracyte's earnings report indicates a disappointing quarter with a larger-than-expected loss per share. The stock reacted slightly down by 0.2%, reflecting investor concerns over the company's current challenges. Without guidance, investors may be uncertain about the company's direction in the near term.
AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.
No charge today · Auto-bills $8/mo after 7 days · Cancel anytime
AMKOR TECHNOLOGY INC
Aug 1, 2016